GTC
MRTX

Ghost Tree Capital’s Mirati Therapeutics, Inc. Common Stock MRTX Stock Holding History

Ghost Tree Capital’s Portfolio MRTX Stock Details MRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-50,000
Closed -$11M – 58
2020
Q4 		$11M Buy
+50,000
New +$10.8M 2.45% 17

Other funds holding MRTX

Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
SS
Simplicity Solutions Minneapolis, Minnesota $3.66B AUM 23.51% 1-Year Est. Return
B
Braslyn New Providence, Bahamas $7.81M AUM 338.68% 1-Year Est. Return

Ghost Tree Capital's MRTX Position: Q4 2023 in Review

Ghost Tree Capital sold out of Mirati Therapeutics, Inc. Common Stock (MRTX) in Q4 2023, closing a stake of 60,000 shares — an estimated $2.61M sold.

Ghost Tree Capital first reported a position in MRTX in Q4 2015 and held it in 30 quarters. The position peaked at $34.5M in Q2 2019. 217 funds tracked by Wall St. Rank hold MRTX as of Q4 2023.

  • Ghost Tree Capital reported no remaining Mirati Therapeutics, Inc. Common Stock position as of Q4 2023 after selling out during the quarter.
  • Ghost Tree Capital sold 60,000 Mirati Therapeutics, Inc. Common Stock shares in Q4 2023, an estimated $2.61M.
  • Ghost Tree Capital first reported a position in Mirati Therapeutics, Inc. Common Stock in Q4 2015 and held it in 30 quarters.
  • Ghost Tree Capital's Mirati Therapeutics, Inc. Common Stock position peaked at $34.5M in Q2 2019.
  • 217 funds tracked by Wall St. Rank held Mirati Therapeutics, Inc. Common Stock as of Q4 2023.

Based on Ghost Tree Capital's 13F filing for Q4 2023, filed 14 Feb 2024.